Digital Self-Management and Peer Mentoring Intervention
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Jan 2, 2025
Trial Information
Current as of August 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The purpose of the study is to determine the efficacy of the Managing Your Health intervention to improve self-management of survivorship care among young adult survivors of childhood cancer.
Aim 1: Evaluate the efficacy of the Managing Your Health intervention. Aim 2: Determine the mechanisms through which Managing Your Health influences outcomes.
Aim 3: Identify subgroups of participants for which treatment effects vary to inform future scale up.
Managing Your Health will be tested in a two-arm parallel randomized controlled trial (RCT) of the intervention versus usual care + education...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Diagnosis with any malignant childhood cancer between the ages 0-19 at least 5 years prior
- • 2. Cancer treatment occurred at a pediatric center/facility
- • 3. Current age 18-25
- • 4. At least 2 years from treatment completion (typical time for transfer to long-term follow-up care)
- Exclusion Criteria:
- • 1. Any documented physical or self-reported cognitive delay that could prevent self-management of health care
- • 2. Diagnoses of cancer not typically considered pediatric (I.e., melanoma, carcinoma of the breast, colorectum, lung, ovary, and testicle)
- • 3. Unable to speak/read English
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
New Brunswick, New Jersey, United States
Patients applied
Trial Officials
Kristine Levonyan-Radloff, MS
Study Director
Rutgers Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported